| Amy Hajari Case, MD | |
|
3820 Medical Park Dr, Austell, GA 30106-1110 | |
| (770) 948-6041 | |
| (770) 739-5411 |
| Full Name | Amy Hajari Case |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 19 Years |
| Location | 3820 Medical Park Dr, Austell, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467664466 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Hospital | Atlanta, GA | Hospital |
| Piedmont Fayette Hospital | Fayetteville, GA | Hospital |
| Piedmont Mountainside Hospital Inc | Jasper, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Specialty Hospital Billing Llc | 4183986490 | 179 |
| Piedmont Providers Llc | 9830082825 | 371 |
News Archive
Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
BIOTRONIK SE & Co. KG announced today the start of the NORDIC ICD clinical trial. The first implantable cardioverter defibrillator (ICD) patients were enrolled by its coordinating clinical investigator, Prof. Dr. Dietmar Bänsch at the University Hospital of Rostock and the investigator Dr. Stefan Kuster at the DRK Hospital of Mölln/Ratzeburg.
A new study published in the September issue of Health Affairs focuses on the cost of care delivered by nearly 250,000 doctors to non-elderly adults.
Urine testing may be as effective as the smear test at preventing cervical cancer, according to new research by University of Manchester scientists.
› Verified 5 days ago
| Entity Name | Piedmont Providers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548273592 PECOS PAC ID: 9830082825 Enrollment ID: O20040204000321 |
News Archive
Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
BIOTRONIK SE & Co. KG announced today the start of the NORDIC ICD clinical trial. The first implantable cardioverter defibrillator (ICD) patients were enrolled by its coordinating clinical investigator, Prof. Dr. Dietmar Bänsch at the University Hospital of Rostock and the investigator Dr. Stefan Kuster at the DRK Hospital of Mölln/Ratzeburg.
A new study published in the September issue of Health Affairs focuses on the cost of care delivered by nearly 250,000 doctors to non-elderly adults.
Urine testing may be as effective as the smear test at preventing cervical cancer, according to new research by University of Manchester scientists.
› Verified 5 days ago
| Entity Name | Piedmont Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376624940 PECOS PAC ID: 3274529524 Enrollment ID: O20040423000767 |
News Archive
Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
BIOTRONIK SE & Co. KG announced today the start of the NORDIC ICD clinical trial. The first implantable cardioverter defibrillator (ICD) patients were enrolled by its coordinating clinical investigator, Prof. Dr. Dietmar Bänsch at the University Hospital of Rostock and the investigator Dr. Stefan Kuster at the DRK Hospital of Mölln/Ratzeburg.
A new study published in the September issue of Health Affairs focuses on the cost of care delivered by nearly 250,000 doctors to non-elderly adults.
Urine testing may be as effective as the smear test at preventing cervical cancer, according to new research by University of Manchester scientists.
› Verified 5 days ago
| Entity Name | Piedmont Specialty Hospital Billing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699290510 PECOS PAC ID: 4183986490 Enrollment ID: O20180327001180 |
News Archive
Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
BIOTRONIK SE & Co. KG announced today the start of the NORDIC ICD clinical trial. The first implantable cardioverter defibrillator (ICD) patients were enrolled by its coordinating clinical investigator, Prof. Dr. Dietmar Bänsch at the University Hospital of Rostock and the investigator Dr. Stefan Kuster at the DRK Hospital of Mölln/Ratzeburg.
A new study published in the September issue of Health Affairs focuses on the cost of care delivered by nearly 250,000 doctors to non-elderly adults.
Urine testing may be as effective as the smear test at preventing cervical cancer, according to new research by University of Manchester scientists.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Hajari Case, MD 3820 Medical Park Dr, Austell, GA 30106-1110 Ph: (770) 948-6041 | Amy Hajari Case, MD 3820 Medical Park Dr, Austell, GA 30106-1110 Ph: (770) 948-6041 |
News Archive
Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
BIOTRONIK SE & Co. KG announced today the start of the NORDIC ICD clinical trial. The first implantable cardioverter defibrillator (ICD) patients were enrolled by its coordinating clinical investigator, Prof. Dr. Dietmar Bänsch at the University Hospital of Rostock and the investigator Dr. Stefan Kuster at the DRK Hospital of Mölln/Ratzeburg.
A new study published in the September issue of Health Affairs focuses on the cost of care delivered by nearly 250,000 doctors to non-elderly adults.
Urine testing may be as effective as the smear test at preventing cervical cancer, according to new research by University of Manchester scientists.
› Verified 5 days ago
Y Khalid Siddiq, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 Hospital South Dr, Suite 200, Austell, GA 30106 Phone: 770-948-5578 | |
Dr. Yousef Hindi, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3950 Austell Rd, Austell, GA 30106 Phone: 770-732-4025 Fax: 770-732-4023 | |
Dr. Manu Malepati, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3950 Austell Rd, Box 22, Austell, GA 30106 Phone: 470-732-4022 Fax: 470-732-4023 | |
Dr. Alaa El-din Soltan, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1668 Mulkey Rd Ste 164, Austell, GA 30106 Phone: 770-948-3233 Fax: 770-944-1537 | |
Ryan P Carrick, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3820 Medical Park Dr., Austell, GA 30106 Phone: 770-948-6041 | |
Dr. Jacob Nathan Blatt, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 Hospital South Dr, Suite 409, Austell, GA 30106 Phone: 770-424-6893 Fax: 770-528-9926 | |
Rashila Byrd, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3825 Medical Park Dr Ste 300, Austell, GA 30106 Phone: 770-941-4810 Fax: 770-948-9149 |